Society of Diabetic Nephropathy Prevention Journal of Nephropharmacology 2345-4202 14 2 2025 07 01 Immune checkpoint inhibitors and IgA nephropathy; A rare side effect e12762 e12762 10.34172/npj.2025.12762 EN Maryam Dehghani Mobarakeh https://orcid.org/0000-0002-4368-3900 Ahmadreza Maghsoudi https://orcid.org/0000-0002-0173-1222 Journal Article 10.34172/npj.2025.12762 2024 12 29 2025 02 14 The pathophysiological mechanisms of secondary IgA nephropathy (IgAN) containing IgA-mediated immune complex deposition in the glomeruli. However, the specific triggers can vary widely, including infections, liver disease, and malignancies, in addition to drug-induced factors. IgAN is a rare however is a serious complication of immune checkpoint inhibitor (ICI) therapy that can lead to acute kidney injury. Clinically, the diagnosis of sIgAN typically follows a temporal association between medication administration and the onset of renal symptoms, such as hematuria or proteinuria. A kidney biopsy is often necessary to confirm the diagnosis and rule out other causes of nephropathy